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Summary. The tumor marker, D-galactose-B[1-31-N- 
acetyl-D-galactosamine (Gal-GalNAc, also known as T- 
antigen) can be identified by a very simple galactose 
oxidase-Schiff 's (GOS) reaction either on tissues or on 
rectal mucus samples from patients with colorectal 
neoplasms. Gal-GalNAc is expressed in the neoplastic 
mucosa as well as the remote non-neoplastic mucosa. It 
is, however, not expressed in colonic mucosa of normal 
subjects. We studied the expression of Gal-GalNAc by 
GOS reaction, lectin reactivity and immunocyto- 
chemistry in 10 normal, 45 precancerous [5 Crohn's 
disease, 15 ulcerative colitis (5 without dysplasia and 10 
with dysplasia),  25  tubular adenomas] ,  and 25  
adenocarcinoma cases. Normal mucosa remote from 
tubular adenoma and adenocarcinoma was also studied. 
The GOS method was compared with reactivity of the 
lectin jacalin and immunostaining with antibody to T 
antigen (Anti-Tag Ab). GOS reaction was negative in all 
of the 10 normal specimens. Of the 5 Crohn's disease 
specimens, 2 were positive and 3 negative. In the 5 
ulcerative colitis cases without dysplasia, positive 
reaction was seen in 2 cases and negative in 3. Of the 10 
cases of ulcerative colitis with dysplasia, 5 showed 
positivity in dysplastic areas, and 3 of these were also 
positive in remote non dysplastic mucosa. Twenty of 25 
tubular adenomas yielded a positive reaction in the 
adenoma, 14 of them showing positivity also in remote 
mucosa; 3 cases showed a positive reaction only in 
remote mucosa. Of the 25 adenocarcinomas, 21 showed 
a positive reaction in the adenocarcinoma as well as the 
remote mucosa. GOS reaction was intense in well 
differentiated adenocarcinoma and weak in poorly 
differentiated adenocarcinoma. Intense reaction was also 
seen in the intracellular mucus of some aberrant crypts 
and morphologically normal crypts remote from adeno- 
carcinoma and tubular adenoma. GOS reaction showed 
an overall sensitivity of 75.7% and specificity of 100% 
for cancer and precancerous lesions. Jacalin reactivity 
was slightly more sensitive (84.3%) but less specific 
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(80%) and Tag Ab reactivity even less sensitive (50%) 
but as specific (100%) for neoplastic and dysplastic 
mucosa. We conclude that the detection of the carbo- 
hydrate moiety Gal-GalNAc varies with the technique 
used. Compared to other techniques, GOS reaction is 
extremely simple and has a high degree of sensitivity 
and specificity. It can be used for detection of this tumor 
marker in remote non-neoplastic mucosa of patients with 
neoplasia or at risk of developing neoplasia. It, therefore, 
could be used as a cost effective screening test in rectal 
biopsy specimens of such patients. 
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Introduction 
Adenocarcinoma of the colon is the second most 
frequently diagnosed malignancy as well as the second 
most common cause of cancer death in the United States 
(Parker et al., 1997). It is treatable and often curable 
when localized within the bowel wall. As in other 
cancers, detection of colon cancer at a very early stage 
can reduce the mortality rate. It has been recommended 
that early detection by screening for colon cancer should 
be part of routine care for all adults starting at age 50 
years, especially for those at high risk (those with first 
degree relatives with colon cancer, patients with 
panulcerative colitis, previous colon cancer, a family 
history of cancer, or a history of sporadic colon polyps) 
(Kim and Lance, 1997). Following treatment of colon 
cancer, periodic follow up by laboratory studies and 
physical examination may lead to earlier identification 
and management of recurrent cancer. 
Prevention is an important method for cancer 
control, and primary prevention attempts to reverse 
precancerous lesion or in situ carcinoma to normal or 
stops them from progressing to invasive malignancies in 
population at high risk. Thus, for prevention and early 
detection, the key is to find the marker which is 
differentially expressed in high risk tissues (cancers and 
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precancerous) but not in normal (Yang and Shamsuddin, 
1996). 
The disaccharide moiety D-galactose-&(l -3)-N- 
acetyl-D-galactosamine (Gal-GalNAc), also called 
Thomsen-Friedenreich antigen or T antigen, is a tumor 
associated carbohydrate  that has been used as  a 
biomarker of colonic cancer and other adenocarcinomas 
(Springer, 1984; Shamsuddin et al., 1995; Carter et el., 
1997). Shamsuddin and Elsayed provided a new test for 
mass screening of colorectal cancer that is based on the 
enzymatic oxidation of Gal-GalNAc by the enzyme D- 
galactose oxidase followed by Schiff 's reagent to 
produce a magenta coloration (Shamsuddin and Elsayed, 
1988). The test was used in rectal mucus samples of 
patients with colorectal neoplasms. Studies done mostly 
in China and Japan confirmed the sensitivity and 
specificity of the test for detection of colorectal neo- 
plasms and precancerous conditions (Sakamoto et al., 
1990, 1993; Zhou et al., 1993; Shamsuddin, 1996). 
Other methods of detection of the T antigen have also 
been reported. These are reactivity with the lectin jacalin 
and immunoreactivity by using an antibody to it in an 
immunoperoxidase reaction (Hanisch and Baldus, 1997). 
In this study we investigated the sensitivity and 
specificity of detection of Gal-GalNAc by the above 
mentioned three techniques on formalin fixed, paraffin 
embedded tissue sect ions of colorectal  cancers ,  
precancerous lesions and normal colon specimens. 
Materials and methods 
One hundred and thirty colon samples  were 
collected from surgical specimens and autopsies at the 
University of Maryland hospital. The samples comprised 
of 25 cases of colorectal adenocarcinoma (5 well 
differentiated, 8 moderately differantiated, 6 poorly 
differentiated, 6 mucinous adenocarcinoma), 25 cases of 
colorectal adenoma (20 with low grade dysplasia, and 5 
with high grade dysplasia), 20 cases of inflammatory 
bowel disease [5 Crohn's disease, 15 ulcerative colitis(5 
without dysplasia, 4 with low grade dysplasia, and 6 
with high grade dysplasia)], 50 specimens of morpho- 
logically normal mucosa remote from cancers and 
adenoma; 10 specimens of colonic mucosa from normal 
subjects served as negative control. The tissues were 
fixed in 10% buffered formalin and embedded in 
paraffin. All sections were cut to 5 pm and stained 
routinely by hematoxylin and eosin (H&E) for 
histological diagnosis. 
Galactose oxidase-Schiff's reaction procedure 
Paraffin tissue sections were deparaffinized in 
xylene, rehydrated in graded alcohols according to 
standard procedure, and then transferred to PBS (pH 7.0) 
for 1 0  minutes.  They were then f looded with D- 
galactose oxidase solution (100 unitslml; Sigma 
Chemical Co.,  St Louis,  MO) for 1 hour at room 
temperature. The sections were then rinsed in distilled 
water for 10 rnin and stained with 2% Schiffs reagent 
(Sigma Chemical Co., St. Louis, MO) for 10 rnin at 
room temperature. The sections were rinsed in running 
tap water for 10 min, counterstained with haematoxylin 
for 2 secconds,  rinsed with running tap water, 
dehydrated, cleared and mounted. 
Jacalin lmmunoreactivity 
Tissue sect ions of 5 p m  thickness were de- 
paraffinized, rehydrated, and then treated with 0.1% 
trypsin (Sigma Chemical Co., St Louis, MO) and 0.1% 
calcium chloride in phosphate buffer, pH 7.5 at 37 "C for 
10 min. Endogenous peroxidase activity was blocked 
with fresh 3% hydrogen peroxide in methanol for 30 
min. Sections were incubated with biotinylated jacalin 
(115000 dilution; Vector Laboratories, Burlingame, CA) 
for 1 hour. Then the avidin-biotin complex (1:25 
dilution; Vector Laboratories Burlingame, CA) was 
applied for 45 min at room temperature. The sections 
were washed in PBS for 5 minutes, and reacted with 
3,3'-diaminobinzidine (0.02% Sigma Chemical Co., 
St Louis, MO) freshly prepared in 0.05M TRIS buffer 
(pH 7.6) containing 0.015M hydrogen peroxide for 7 
minutes, counterstained with hematoxylin, dehydrated 
and mounted. 
lmmunohistochemistry with anti T-antigen antibody 
The sections were deparffinized, rehydrated and 
treated with 3% hydrogen peroxide in methanol for 30 
min to block endogenous peroxidase. To reduce non 
specific staining, the sections were incubated for 20 min. 
at room temperature with normal horse non immune 
serum (1:100 dilution; Vector Laboratories, Burlingame, 
CA). Excess normal serum was blotted from the slides. 
The sections were then incubated with the primary 
(mouse)  antibody (1 :50  dilution; DAKO, Co. ,  
Carpinteria, CA) for 1 hr at room temperature, washed 3 
times for 5 rnin each in PBS (pH 7.2), and incubated 
with biotinylated secondary (horse anti mouse IgG) 
antibody (1:100 dilution; Vector Laboratories,  
Burl ingame,  CA)  in PBS for 30  rnin at room 
temperature. Avidin-biotin complex (1:25 dilution; 
Vector Laboratories, Burlingame, CA) was then applied 
for 60 min. Sections were then incubated with 0.02% 
3,3-diaminobenzidine, freshly prepared in 0.05M TRIS 
buffer (pH 7.6) containing 0.015M hydrogen peroxide, 
and then counterstained with haematoxylin before 
dehydrating and mounting. 
Mucosa from colloid carcinoma patient was used as 
a positive control in each staining run. 
Results 
The staining pattern by GOS, jacalin, and anti T- 
antigen antibody was similar. The positive reaction was 
seen at the apical cell membrane, goblet cell vacuoles 
extracellular mucus, intraluminal mucus, and in the 
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cytoplasm of signet ring cells. Colorectal carcinoma 
Normal colon 
No expression of Gal-GalNAc was detected by GO- 
Schiff's (GOS) and anti-Tag Ab in the epithelia1 cells in 
the 10  normal colon specimens. Weak staining was 
observed with the lectin jacalin in two of the 10 cases. 
Ulcerative colitis and Crohn's disease 
The expression of Gal-GalNAc was seen by GOS in 
2 of 5 (40%) specimens of ulcerative colitis without 
dysplasia, 2 of 6 (30%) specimens of ulcerative colitis 
with low grade dysplasia and 3 of 4 (75%) specimens 
with high grade dysplasia. GOS reactivity was seen in 
the dilated and distorted crypts or even in normal 
appearing crypts (Fig. 1) and focally in dysplastic crypts. 
Two of 5 (40%) specimens of Crohn's disease stained 
positive with GOS. Staining with lectin jacalin was seen 
in 2 of 5 (40%) specimens of ulcerative colitis with no 
dysplasia, 5 of 6 (83%) specimens with low grade 
dysplasia, 3 of 4 (75%) specimens of ulcerative colitis 
with high grade dysplasia the reaction was seen in the 
dysplastic and non dysplastic areas in ulcerative colitis, 
and 2 of 5 cases of Crohn's disease. Gal-GalNAc 
expression was seen by anti-Tag Ab only in 4 of 15 
(26%) specimens of ulcerative colitis, in 1 case without 
dysplasia and in 3 cases with high grade dysplasia, and 
in 1 of 5 cases of Crohn's disease. 
Tubular adenomas 
Expression of Gal-GalNAc was seen by GOS in 15 
of the 20 (75%) tubular adenomas with low grade 
dysplasia and in all 5 tubular adenomas with high grade 
dysplasia. The intensity of staining was strong in all 
cases and was observed in the mucus cells of normal as 
well as dysplastic crypts (Fig. 2) The lectin jacalin 
stained 19 of 20 (95%) tubular adenomas with low grade 
dysplasia, and all five cases (100%) of adenomatous 
polyps with high grade dysplasia. However, the stromal 
cells also showed a non specific weak positive reaction 
(Fig. 3). The expression of Gal-GalNAc was detected by 
anti-Tag Ab only in 12 of 20 (60%) adenomatous polyps 
with low grade dysplasia and in 3 of 5 (60%) 
adenomatous polyps with high grade dysplasia. 
Table 1. The expression of Gal-GalNAc in tubular adenomas, adeno- 
carcinomas, and remote mucosa 
Specimen Technique 
GOS Jacalin Anti-T antigen 
Adenoma =25 20 (80%) 24 (96%) 15 (60%) 
Remote mucosa 17 (68%) 24 (96%) 0 (0%) 
Carcinoma =25 21 (84%) 23 (92%) 15 (60%) 
Remote mucosa 21 (84%) 23 (92%) 15 (60%) 
The GOS reaction was positive in 21 of 25 (84%) 
cancer specimens. The  well differentiated and 
moderately differentiated adenocarcinomas showed 
more intense staining than poorly differentiated adeno- 
carcinoma. The GOS reaction was strong in 5 of the 5 
(100%) well differentiated carcinomas and 6 of 8 (75%) 
moderately differentiated carcinomas (Fig. 4). Reactivity 
was observed in all 6 cases (100%) of mucinous 
carcinoma (Fig. 5). A moderate to weak cytoplasmic 
staining was observed in 4 of 6 (66%) poorly differen- 
tiated carcinomas. The expression of Gal-GalNAc with 
lectin jacalin was seen in 23 of the 25 (92%) cases of 
adenocarcinoma (Fig. 6). Intense reactivity was observed 
in all of cases of mucinous adenocarcinoma as well as all 
cases of well differentiated and moderately differentiated 
adenocarcinomas. Two of the poorly differentiated 
adenocarcinomas did not show staining. Once again, the 
neoplastic glandular elements and to a lesser degree, the 
stromal cells showed positive reaction. 
The expression of Gal-GalNAc by anti-Tag Ab in 15 
of the 25 (60%) cases of adenocarcinoma intense 
staining was observed in only 4 of these; all of them 
being mucinous carcinoma. The well differentiated and 
moderate differentiated adenocarcinoma showed positive 
reaction in 8 of the 13 (61%) cases (Fig. 7), and 3 of the 
6 cases (50%) of poorly differentiated carcinoma were 
positive. 
Crypts adjacent to and remote from carcinoma 
We studied the expression of Gal-GalNAc in normal 
crypts, dilated crypts and distorted crypts (abnormal or 
aberrant crypts) remote from 25 adenocarcinomas and 
25 tubular adenomas. Remote mucosa was stained in 17 
of 25 cases of tubular adenoma by the GOS reaction. 
Fourteen of these cases showed positive reaction in the 
adenomatous epithelium. In 3 cases only the remote 
mucosa stained. The staining was seen in the goblet cell 
vacuoles and intraluminal mucin of morphologically 
normal, dilated and distorted crypts remote from cancer. 
All 21 adenocarcinoma cases that had a positive reaction 
with the GOS sequence also showed positive staining of 
the remote mucosa. GOS reactivity was seen in 2 
specimens of ulcerative colitis with dysplasia and in l 
without dysplasia. Jacalin staining was observed in the 
remote mucosa of all 24 cases and that stained positively 
in the tubular adenoma and in all 23  cases of 
adenocarcinoma that stained positively in their tumor. 
Jacalin reactivity was seen in 3 specimens of ulcerative 
colitis with dysplasia and in 2 without dysplasia. The 
anti-Tag antibody did not stain the remote mucosa in any 
case of adenoma or adenocarcinoma (Table 1). 
Discussion 
The disaccharide Gal-GalNAc, also known as Tag, is 
a precursor of the M and N blood group substances. Gal- 
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GalNAc normally contains a sialic acid that is attached 
to the terminal galactose. It is believed that removal of 
sialic acid allows the sugar moiety to be oxidized by the 
enzyme galactose oxidase (Shamsuddin, 1991; Hanisch 
and Baldus, 1997). Schulte and Spicer (1983) first 
demonstrated the use of the enzyme D-galactose oxidase 
to study Tag in rat tracheal gland secretory glyco- 
proteins. The enzyme D-galactose oxidase specifically 
oxidizes C-6 hydroxyl groups of D-galactopyranose and 
N-acetylgalactosamine residues of Gal-GalNAc, 
generating two vicinal aldehyde groups, which react 
with basic fuchsin to give magentalpurple coloration, 
called galactose-oxidase-Schiff or GOS reaction 
(Shamsuddin and Elsayed, 1988). It is believed that 
sialic acid free Gal-GalNAc is present in mucus of 
colorectal cancer and precancer of both human and 
experimental animals, but not in normal mucin 
(Shamsuddin, 1991, 1996). In 1981, Shamsuddin et al. 
first proposed that the mucin composition is altered 
throughout the entire colon in patients with colonic 
cancer and precancer by the way of the generalized field 
effect of carcinogens. One abnormality may be the loss 
of the terminal sialic acid residues, leaving Gal-GalNAc 
exposed. This alteration may be due to reduction of 
glycosyltransferases, leading to aberrant or incomplete 
glycoprotein synthesis (Shamsuddin et al., 1981). Based 
on this hypothesis, Shamsuddin developed a simple 
test, using the GOS technique, to detect the marker 
Gal-GalNAc in the rectal mucus of patients with 
precancerous and cancerous lesions of the colon 
(Shamsuddin, 1994; Shamsuddin and Sakamoto, 1994). 
Jacalin is an IgA specific lectin isolated from dried 
seeds of jack fruit, Arlocarpus intergrifolia and interacts 
Table 2. Sensitivity and specificity of different methods of Gal-GalNAc 
detection 
with D-galactose (Urdiales-Viedma et al., 1995). It is 
able to bind to Gal-GalNAc residues that are 0 -  
glycosically linked to serine or threonine. The major 
component of the active lectin seems to be a molecule of 
about 54,000 dalton and probably made up of three 
non-glycosylated non covalently linked subunits 
(Aucouturier et al., 1987). There are few reports about 
reactivity of the lectin jacalin on tissue sections. Muscle 
fibers in ten days-old rats were stained with jacalin 
(Kirkeby et al., 1992) and it also binds selectively to 
goblet cells in conjuctival tissue (Prause et al., 1989). 
Urdiales-Viedma et al. (1995) observed that jacalin 
stains histiocytes in paraffin embedded tissues in all 
cases of reactive sinus histiocytosis, and macrophages in 
follicular hyperplasia and in granulomas of tuberculosis. 
They failed to find any staining in cases of eosinophilic 
granulomas, giant cell tumors of tendon sheath, 
pleomorphic fibrous histiocytomas, and in Hodgkin's 
disease. They concluded that jacalin could be used as a 
marker for detection and differentiation of histiocytesl 
macrophages from histiocyte mimicking cells. We could 
not find any report of use of jacalin in colorectal tumors. 
Thus, this is the first study of jacalin reactivity in 
colorectal tumors. However, its usefulness is limited by 
its non-specific reactivity or cross reactivity to the 
stromal cells perhaps containing sialylated Gal-GalNAc. 
Gal-GalNAc can also be detected by using mono- 
clonal or polyclonal antibodies to T antigen (Hanisch 
and Baldus, 1997). Using monoclonal antibodies, 
conflicting results have been published; most studies 
show positive reactivity of cancer with Tag antibodies 
except monoclonal antibodies HH8 and HT8 which did 
not stain colorectal carcinoma (Orntoft et al., 1990). 
Whereas monoclonal antibody BW 835 has recently 
been characterized to bind to T antigen (Hanisch et al., 
Technique Sensitivity - Specificity Table 3. Comparison of time and steps taken to perform the three tests 
Overall IBD ~d~~~~~ carcinoma for Gal-GalNAc detection on tissue samples. 
GOS 75.7-1 00 45-1 00 92-1 00 84-1 00 Technique Number of steps Total time for reaction 
Jacalin 84.3-80 60-80 96-80 92-80 
T-ag 50-1 00 25-1 00 60-100 60-1 00 GOS 2 1.5 hour 
Jacalin 5 2.5 hour 
IBD: Inflammatory bowel disease. Anti-Tag Ab 6 3.5 hour 
r 
Fig. 1. GOS reaction in ulcerative colitis showing crypt abscess. The abnormal and dilated crypt shows magenta coloration indicating expression of 
Cal-GalNAc. X 400 
Fig. 2. GOS reaction in tubular adenoma. A crypt with mild dysplasia shows magenta reaction in goblet cells. X 960 
Fig. 3. Jacalin staining in tubular adenoma showing positive reaction in adenomatous epithelium and non specific reaction in stroma. X 400 
Fig. 4. GOS reaction in moderate differentiated adenocarcinoma showing magenta reaction in secreted mucus in the lumen. X 400 
Fig. 5. GOS reaction in mucinous adenocarcinoma showing Gal-GalNAc expression in mucus lakes. X 400 
Fig. 6. Jacalin staining in well differentiated adenocarcinoma. X 960 
Fig. 7. Anti T-antigen antibody staining in moderate differentiated adenocarcinoma. X 400 
Gal-GalNAc as a tumor marker 
F' - 
. 
m*,: , . l:. %t,x C.... . --U. , b .. .. 
C-? - . 
Gal-GalNAc as a turnor marker 
1995). 
The present study was undertaken to localize the 
Gal-GalNAc residue on tissue specimens of pre- 
neoplastic and neoplastic colorectal mucosa by GO- 
Schiff's sequence and to compare the results with Jacalin 
and Tag Ab binding reaction. Our results showed the 
following sensitivity and specificity data (Table 2). 
Overall sensitivity for the GOS reaction was 75.7% and 
specificity 100%; for jacalin, 84.3% and 80%, and for 
anti-Tag Ab 50% and 100% respectively. For pre- 
cancerous lesions, the sensitivity and specificity figures 
were 71.1% and 100% for GOS, 80% and 80% for 
jacalin, and 44.4% and 100% for anti-Tag Ab. For 
carcinomas these figures were 84% and 100% for GOS, 
92% and 80% for Jacalin and 60% and 100% for anti- 
Tag Ab. For inflammatory bowel disease: 45% and 
100% for GOS, 60% and 80% for jacalin, 25% and 
100% for Tag Ab. For tubular adenoma: 92% and 100% 
for GOS, 96% and 80% for jacalin and 60% and 100% 
for anti-Tag Ab. We found no expression of Gal-GalNAc 
by GOS reaction or anti-Tag Ab in 10 normal colonic 
mucosa specimens. Weak staining was observed in two 
cases with Jacalin. This weak staining was probably due 
to the ability of Jacalin to bind to sialylated Gal-GaMAc 
which may be expressed in normal colonic mucosa 
(Hagiwara et al., 1988; Corbeau et al., 1995). 
We also observed that the expression of Gal-GalNAc 
was more frequent and intense in mucinous and well 
differentiated adenocarcinomas than in poorly 
differentiated adenocarcinomas. This finding supports 
the earlier observation of Springer (1984) that anaplastic 
carcinoma often has greater Tn antigen (a precursor of 
Tag) and T antigen ratio than well differentiated 
adenocarcinoma. Glands, or cells react with GOS, but 
not with jacalin or anti-Tag Ab and vice versa may be 
due to the fact that the Gal-GalNAc detected by GOS is 
different, perhaps they have a different intercarbohydrate 
bond, different degree, and position of sialylation or 
another yet unknown structure. 
The morphologically normal, dilated and distorted 
crypts remote from cancer and adenoma showed 
expression of Gal-GalNAc by GOS in 38 of the 50 cases 
(76%) and by jacalin staining in 47 of 50 (94%) cases. 
The correspondence between increased GOS and jacalin 
reactivity in morphologically normal mucosa remote 
from cancer and the presence of colonic neoplasm 
suggests that the alterations in mucin resulting in 
increased GOS and jacalin reactivity are associated with 
the carcinogenic process (Carter et al., 1997). 
Shamsudddin hypothesized that the histochemically 
altered foci of morphologically normal appearing 
mucosa were perhaps areas of initiated foci, and that 
these may be predictors of cancer away from their site of 
sampling (McKenzie et al., 1987; Shamsuddin, 1991, 
1996). In other words, as a result of generalized effect of 
the carcinogens throughout the entire field of the target 
tissue, it is most likely that the mucosa away from an 
obvious cancer would be abnormal and expressing Gal- 
GalNAc. Shamsuddin also rationalized that: (a) the 
presence of cancer in large intestine implies previous 
exposure of the host to carcinogens; (b) most carcino- 
gens act by field effect, where the entire target tissue is 
subjected to carcinogenic stimuli; (c) carcinogens induce 
multi focal changes throughout the entire target tissue 
viz. colorectal cancer; and (d) of the many initiated sites, 
only some of them may be promoted to recognizable 
cancer (Shamsuddin, 1996). Thus the alterations in 
normal appearing, initiated but not promoted mucosa 
may express some of the markers of cancer and pre- 
cancer, such as Gal-GalNAc. Table 1 and 2 shows that 
GOS is the best technique for detection of Gal-GalNAc 
in remote mucosa. 
Gal-GalNAc expression was also demonstrated in 
other known precancerous conditions of the colonic 
mucosa e.g. ulcerative colitis with and without dysplasia 
and Crohn's disease. This indicates that expression of 
Gal-GalNAc may be one of the earliest phenotypic 
abnormality which may precede morphological changes 
of colorectal neoplasia (McKenzie et al., 1987; Xu et al., 
1992; Yang and Shamsuddin, 1995) and establishes the 
role of Gal-GalNac as a tumor marker. Its presence in 
morphologically normal colonic crypts may be useful in 
determining the malignant potential of that colonic 
mucosa. 
In this study we have shown that the GO-Schiff 'S 
reaction is a sensitive and specific way for detection of 
this marker. The lectin jacalin, although more sensitive, 
is less specific, and the anti-Tag Ab (clone HT8) is much 
less sensitive (Orntoft et al., 1990). Table 3 shows the 
comparison between the 3 different techniques for 
detection Gal-GalNAc. Note that GOS is the simplest 
and the fastest of all 3 reactions yet yielding the best 
overall sensitivity. 
In conclusion, The GOS reaction has the potential to 
identify the tumor marker Gal-GalNAc either at the 
tissue level or by mucin test. This test, simplest of all the 
three, could be used for screening and early detection of 
colorectal cancer and precancerous lesions (Yang and 
Shamsuddin, 1996; Shamsuddin 1996). Furthermore, 
studies have shown that Gal-GaMAc expression can be 
suppressed by cancer chemopreventive and chemo- 
therapeutic agent IP6. Following IP treatment, HT-29 
human colon carcinoma cells terminafly differentiate and 
produce mucin, yet not Gal-GalNAc (Sakamoto et al., 
1993; Yang and Shamsuddin, 1995). Thus Gal-GalNAc 
can also serve as biomarker to monitor the efficacy of 
chemoprevention. 
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